Clin2
NCT07159412Possibly a fitNot yet recruiting

Huazhi Rougan Granule for H. pylori with fatty liver disease

Helicobacter Pylori InfectionMetabolic-associated SteatohepatitisHigh-dose Dual TherapyHuazhi Rougan Granule

Part of Digestive system, Hormones & metabolism, Infections clinical trials.

This trial tests if adding Huazhi Rougan Granule to standard H. pylori treatment helps patients who also have a type of fatty liver called MASH. It focuses on people with a specific pattern in traditional Chinese medicine called dampness-heat accumulation.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
286 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have both H. pylori infection (confirmed by a breath test) and metabolic-associated steatohepatitis (MASH), a type of fatty liver.
  • Your condition matches the traditional Chinese medicine pattern of 'dampness-heat accumulation' (your doctor can tell you if this applies).
  • You have not been treated for H. pylori before.
  • You are not pregnant or breastfeeding, and you do not have advanced liver problems like cirrhosis.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06901375Not yet recruiting· Early Phase 1
Chinese herbal remedy plus antibiotics for H. pylori infection

This study tests whether a traditional Chinese herbal formula (Zuojin Wan) plus antibiotics (vonoprazan and amoxicillin) can better treat H. pylori infection in people with functional dyspepsia. It may offer an alternative for those who haven't had success with standard treatment.

Nanjing, Jiangsu
NCT07537634Recruiting· Phase 4
New stomach acid medicine versus standard treatment for H. pylori infection

This trial compares two different antibiotic combinations to treat H. pylori, a common stomach bacteria that causes indigestion and ulcers. One uses a newer acid-blocking medicine (vonoprazan) and the other uses a standard one (esomeprazole), both paired with antibiotics.

Dhaka
NCT06929962Recruiting· Phase 4
VA dual sequential therapy for H. pylori gastritis

This trial tests a new two-step antibiotic treatment for adults with chronic gastritis caused by H. pylori bacteria. If you have not been treated for H. pylori before and are between 18 and 70, you may be able to join.

Nanjing, Jiangsu
NCT07624422Not yet recruiting· Phase 4
Two antibiotic combinations for H. pylori stomach infection

This study compares two different antibiotic treatment plans for H. pylori, a common stomach bacteria that causes ulcers and digestive problems. The trial tests whether a higher dose of one medication (vonoprazan) works better than a different antibiotic combination.

Damascus
NCT07306988Recruiting· Phase 4
Treating H. pylori to improve metabolic syndrome

This trial tests whether treating H. pylori infection can help improve metabolic syndrome (a group of conditions like high blood sugar, abnormal cholesterol, and high blood pressure). It aims to understand how treatment changes your gut bacteria and overall health.

Nanjing, Jiangsu
NCT07663643Not yet recruiting· Phase 4
Study of Fuzheng Huayu tablets for fatty liver with cirrhosis

This trial tests whether Fuzheng Huayu tablets can help people with fatty liver disease that has progressed to cirrhosis (scarring) that is still compensated (the liver is still working well). The goal is to see if the tablets slow or reverse liver damage.

Hear when a new Helicobacter Pylori Infection trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.